How does EMA approval differ from FDA approval?

The European Medicines Agency (EMA) is the regulatory body responsible for drug approvals in the European Union. The US Food and Drug Administration (FDA) is the equivalent for the United States. Both agencies apply broadly similar scientific standards — pivotal randomised controlled trials, well-characterised manufacturing, appropriate labelling — but they reach independent decisions and their timelines, evidentiary preferences, and post-market frameworks differ.

For most of the major peptide approvals in this catalog, both agencies have approved the compound within a similar timeframe (semaglutide, tirzepatide, tesamorelin, elamipretide all have both EMA and FDA approvals in their principal indications). But there are notable divergences. Melanotan I (afamelanotide, Scenesse) was approved by EMA in 2014 for erythropoietic protoporphyria five years before its FDA approval in 2019. Thymosin alpha-1 (Zadaxin) is approved in over 35 countries — mostly outside the US and EU — and has never received either FDA or EMA approval; the Chinese, Italian, and other regulatory approvals are what support its Zadaxin brand internationally. These regional differences reflect not only scientific evidence but the specific evidence packages each sponsor submitted and the specific market strategies pursued.

Other major regulators include MHRA (UK), PMDA (Japan), TGA (Australia), Health Canada, and the Chinese NMPA. Each is a sovereign approval decision. Compound pages that carry multi-regulator status tags (e.g. fda-approved + ema-approved + mhra-approved) are documenting each of these independent decisions. Approval in one region does not automatically confer approval in another; each requires its own regulatory pathway.